The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded a $403,687 project grant to Rutgers, The State University of New Jersey, to develop a universal CAR macrophage cell therapy for pancreatic cancer treatment. The research project aims to demonstrate the anti-tumor effects of these CAR macrophage cells as an adjuvant therapy to KRAS inhibitors in both human pancreatic cancer xenograft models and mouse spontaneous pancreatic cancer models. The key objectives are to validate the phagocytic and cytotoxic activities of the CAR macrophages against pancreatic cancer cells, characterize the tumor microenvironment remodeling, and assess the potential for this therapy to improve outcomes when combined with standard KRAS-targeted treatments. The award period runs from July 1, 2024 to June 30, 2026.
Generated 1/28/25, 10:09 AM